Bilirubin exerts pro-angiogenic property through Akt-eNOS-dependent pathway

Hypertension Research

Volumn 38, Issue 11, 2015, Pages 733-740

  Ikeda, Yasumasa ^a   Hamano, Hirofumi ^a,b   Satoh, Akiho ^a   Horinouchi, Yuya ^a,b   Izawa Ishizawa, Yuki ^a   Kihira, Yoshitaka ^a   Ishizawa, Keisuke ^a,b   Aihara, Ken Ichi ^a   Tsuchiya, Koichiro ^a   Tamaki, Toshiaki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

angiogenesis; bilirubin; endothelial cells; eNOS

Indexed keywords

BILIRUBIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; ANTIOXIDANT; NOS3 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3 KINASE; SUPEROXIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CAPILLARY DENSITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG MECHANISM; FOOD INTAKE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; ISCHEMIC HINDLIMB; LEG ISCHEMIA; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; HINDLIMB; ISCHEMIA; METABOLISM; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANTIOXIDANTS; BILIRUBIN; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HINDLIMB; HUMANS; ISCHEMIA; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SUPEROXIDES;

EID: 84946558014     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2015.74     Document Type: Article

References (46)

1. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344: 581-590
2. Owens D, Evans J. Population studies on Gilbert's syndrome. J Med Genet 1975; 12: 152-156
3. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotný L, Kotal P. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002; 160: 449-456
4. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994; 40: 18-23
5. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16: 250-255
6. Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke 2001; 32: 580-583
7. Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, Baycan ST, Muderrisoglu H. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 2006; 184: 431-437
8. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008; 121: 781-788 e781
9. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009; 40: 3422-3427
10. Li RY, Cao ZG, Zhang JR, Li Y, Wang RT. Decreased serum bilirubin is associated with silent cerebral infarction. Arterioscler Thromb Vasc Biol 2014; 34: 946-951
11. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1046
12. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Higashi Y. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol 2013; 33: 1401-1408
13. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008; 28: 166-172
14. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-2578
15. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-1010
16. Chen LL, Yin H, Huang J. Inhibition of TGF-beta1 signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis. Cardiovasc Pathol 2007; 16: 221-230
17. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-3139
18. Murohara T, Witzenbichler B, Spyridopoulos I, Asahara T, Ding B, Sullivan A, Losordo DW, Isner JM. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 1999; 19: 1156-1161
19. Gullu H, Erdogan D, Tok D, Topcu S, Caliskan M, Ulus T, Muderrisoglu H. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler Thromb Vasc Biol 2005; 25: 2289-2294
20. Ikeda Y, Tajima S, Yoshida S, Yamano N, Kihira Y, Ishizawa K, Aihara K, Tomita S, Tsuchiya K, Tamaki T. Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis 2011; 215: 339-347
21. Ikeda Y, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Yoshida S, Aihara K, Tsuchiya K, Tamaki T. Bovine milk-derived lactoferrin exerts proangiogenic effects in an Src-Akt-eNOS-dependent manner in response to ischemia. J Cardiovasc Pharmacol 2013; 61: 423-429
22. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2: 329-333
23. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605
24. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601
25. Levine YC, Li GK, Michel T. Agonist-modulated regulation of AMP-Activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK-4 Rac1-4 Akt-4 endothelial nitric-oxide synthase pathway. J Biol Chem 2007; 282: 20351-20364
26. Tanaka M, Fukui M, Okada H, Senmaru T, Asano M, Akabame S, Yamazaki M, Tomiyasu K, Oda Y, Hasegawa G, Toda H, Nakamura N. Low serum bilirubin concentration is a predictor of chronic kidney disease. Atherosclerosis 2014; 234: 421-425
27. Abbasi A, Deetman PE, Corpeleijn E, Gansevoort RT, Gans RO, Hillege HL, van der Harst P, Stolk RP, Navis G, Alizadeh BZ, Bakker SJ. Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study. Diabetes 2014; 64: 1459-1469
28. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, Hasegawa G, Nakamura N. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 2008; 74: 1197-1201
29. Riphagen IJ, Deetman PE, Bakker SJ, Navis G, Cooper ME, Lewis JB, de Zeeuw D, Lambers Heerspink HJ. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. Diabetes 2014; 63: 2845-2853
30. Fujii M, Inoguchi T, Sasaki S, Maeda Y, Zheng J, Kobayashi K, Takayanagi R. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010; 78: 905-919
31. Ikeda N, Inoguchi T, Sonoda N, Fujii M, Takei R, Hirata E, Yokomizo H, Zheng J, Maeda Y, Kobayashi K, Takayanagi R. Biliverdin protects against the deterioration of glucose tolerance in db/db mice. Diabetologia 2011; 54: 2183-2191
32. Pflueger A, Croatt AJ, Peterson TE, Smith LA, d'Uscio LV, Katusic ZS, Nath KA. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 2005; 288: F552-F558
33. Vera T, Granger JP, Stec DE. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol 2009; 297: R738-R743
34. Dekker D, Dorresteijn MJ, Pijnenburg M, Heemskerk S, Rasing-Hoogveld A, Burger DM, Wagener FA, Smits P. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2011; 31: 458-463
35. Galasso G, Schiekofer S, Sato K, Shibata R, Handy DE, Ouchi N, Leopold JA, Loscalzo J, Walsh K. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. Circ Res 2006; 98: 254-261
36. Haddad P, Dussault S, Groleau J, Turgeon J, Michaud SE, Ménard C, Perez G, Maingrette F, Rivard A. Nox2-containing NADPH oxidase deficiency confers protection from hindlimb ischemia in conditions of increased oxidative stress. Arterioscler Thromb Vasc Biol 2009; 29: 1522-1528
37. El-Azab MF, Hazem RM, Moustafa YM. Role of simvastatin and/or antioxidant vitamins in therapeutic angiogenesis in experimental diabetic hindlimb ischemia: effects on capillary density, angiogenesis markers, and oxidative stress. Eur J Pharmacol 2012; 690: 31-41
38. Kito T, Shibata R, Kondo M, Yamamoto T, Suzuki H, Ishii M, Murohara T. Nifedipine ameliorates ischemia-induced revascularization in diet-induced obese mice. Am J Hypertens 2012; 25: 401-406
39. Pattillo CB, Bir SC, Branch BG, Greber E, Shen X, Pardue S, Patel RP, Kevil CG. Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress. Free Radic Biol Med 2011; 50: 262-269
40. Polytarchou C, Papadimitriou E. Antioxidants inhibit human endothelial cell functions through down-regulation of endothelial nitric oxide synthase activity. Eur J Pharmacol 2005; 510: 31-38
41. Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res 2012; 35: 1039-1047
42. Davis PA, Pagnin E, Dal Maso L, Caielli P, Maiolino G, Fusaro M, Paolo Rossi G, Calò LA. SIRT1, heme oxygenase-1 and NO-mediated vasodilation in a human model of endogenous angiotensin II type 1 receptor antagonism: implications for hypertension. Hypertens Res 2013; 36: 873-878
43. Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, Csizmadia E, Graça-Souza AV, Liloia A, Soares MP, Otterbein LE, Usheva A, Yamashita K, Bach FH. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 2005; 112: 1030-1039
44. Dong H, Huang H, Yun X, Kim DS, Yue Y, Wu H, Sutter A, Chavin KD, Otterbein LE, Adams DB, Kim YB, Wang H. Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation. Endocrinology 2014; 155: 818-828
45. Wegiel B, Baty CJ, Gallo D, Csizmadia E, Scott JR, Akhavan A, Chin BY, Kaczmarek E, Alam J, Bach FH, Zuckerbraun BS, Otterbein LE. Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J Biol Chem 2009; 284: 21369-21378
46. Liu J, Wang L, Tian X, Liu L, Wong WT, Zhang Y, Han QB, Ho HM, Wang N, Wong SL, Chen ZY, Yu J, Ng CF, Yao X, Huang Y. Unconjugated bilirubin mediates heme oxygenase-1-induced vascular benefits in diabetic mice. Diabetes 2014; 64: 1564-1575